Table 4.
Safety and adverse effects of Shen-Qi-Formula and insulin treatment
| Variable | Ins | SQF+Ins | ||
|---|---|---|---|---|
| Baseline | After 12 weeks | Baseline | After 12 weeks | |
| Laboratory data | ||||
| HGB (g/L) | 134.5 ± 14.2 | 132.1 ± 10 | 135.4 ± 11.3 | 134.2 ± 11.2 |
| ALT (IU/L) | 32.8 ± 20.2 | 29.5 ± 13.7 | 35.6 ± 21.3 | 32.4 ± 19.6 |
| AST (IU/L) | 28.6 ± 20.4 | 26.46 ± 17.1 | 29.1 ± 21.3 | 26.4 ± 1 |
| CCr (mL/min) | 86.2 ± 17.2 | 99.7 ± 13.8 | 89.4 ± 21.4 | 101.7 ± 18.7 |
| BUN (mg/dL) | 16.2 ± 2.6 | 18. 3 ± 3.2 | 17.1 ± 3.4 | 16.9 ± 2.7 |
| Clinical data | ||||
| Loose bowels | 0 | 0 | 0 | 1 |
| Fatigue | 0 | 1 | 0 | 1 |
ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CCr, creatinine clearance rate; HGB, hemoglobin; Ins, insulin; SQF, Shen-Qi-Formula.